Application of a Stochastic Modeling to Assess the Evolution of Tuberculous and Non-Tuberculous Mycobacterial Infection in Patients Treated with Tumor Necrosis Factor Inhibitors

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Agliari, Elena ^a,b   Asti, Lorenzo ^c   Barra, Adriano ^c   Scrivo, Rossana ^c   Valesini, Guido ^c   Wallis, Robert S ^d  

^a UNIVERSITY OF PARMA   (Italy)

^b INFN SEZIONE DI ROMA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; ATYPICAL MYCOBACTERIOSIS; CONCEPTUAL FRAMEWORK; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; HUMAN; LATENT TUBERCULOSIS; MASS SCREENING; MONTE CARLO METHOD; POSTPRIMARY TUBERCULOSIS; PROBABILITY; QUALITATIVE ANALYSIS; RECURRENCE RISK; STOCHASTIC MODEL;

ANTITUBERCULAR AGENTS; DISEASE PROGRESSION; FEASIBILITY STUDIES; HUMANS; LATENT TUBERCULOSIS; MARKOV CHAINS; MONTE CARLO METHOD; RECURRENCE; RISK ASSESSMENT; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873839636     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055017     Document Type: Article

References (38)

1. Tracey D, Klareskog L, Sasso E, Salfeld J, Tak P, (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117: 244-279.
2. Lee D, Weinblatt M, (2001) Rheumatoid arthritis. The Lancet 358: 903-911.
3. Choy E, Panayi G, (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344: 907-916.
4. Elliott M, Maini R, Feldmann M, (1995) TNF alpha blockade in rheumatoid arthritis: rationale, clinical out-comes and mechanisms of action. Int J Immunopharmacol 17: 141-145.
5. Tak P, Kalden J, (2011) Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther 13: 1-14.
6. Gardam M, Keystone E, Menzies R, Manners S, Skamene E, et al. (2003) Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect Dis 3: 148-155.
7. Wallis R, Ehlers S, (2005) Tumor necrosis factor and granuloma biology: Explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 34: 34-38.
8. Wallis R, (2008) Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 8: 601-611.
9. Wallis R, (2008) Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum 58: 947-952.
10. Wallis R, Broder M, Wong Y, Hanson M, Beenhouwer D, (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38: 1261-1265.
11. Plessner H, Lin PL, Kohno T, Louie JS, Kirschner D, et al. (2007) Neutralization of tumor necrosis factor (TNF) by antibody but not tnf receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 195: 1643-50.
12. Clay H, Volkman H, Ramakrishnan L, (2008) Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity 29: 283-94.
13. Lin P, Myers A, Smith L, Bigbee C, Bigbee M, et al. (2010) TNF neutralization results in disseminated disease during acute and latent M. tuberculosis infection with normal granuloma structure. Arthritis Rheum 62: 340-350.
14. Keane J, Gershon S, Wise R, Mirabile-Levens E, Kasznica J, et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098-104.
15. Iliopoulos A, Kedikoglou S, Laxanis S, Kourouklis S, Katsaros E, (2006) A case of tuberculous meningoencephalitis in a patient with Behcet's disease. Clin Rheumatol 25: 121-2.
16. Liberopoulos E, Drosos A, Elisaf M, (2002) Exacerbation of tuberculosis enteritis after treatment with infliximab. Am J Med 113: 615.
17. Verhave JC, van Altena R, Wijnands M, Roerdink H, (2008) Tuberculous peritonitis during infliximab therapy. Neth J Med 66: 77-80.
18. Schiff M, Burmester G, Kent J, Pangan A, Kupper H, et al. (2006) Safety analysis of adalimumab (humiraæ) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65: 889-894.
19. Scrivo R, Sauzullo I, Mengoni F, Iaiani G, Vestri A, et al. (2012) Serial interferon- release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents. Clin Rheumatol 31: 1567-1575.
20. Scrivo R, Sauzullo I, Mengoni F, Priori R, Coppola M, et al. (2012) Mycobacterial IFN-gamma release variations during long-term treatment with TNF blockers: lack of correlation with clinical outcome. J Rheumatol (in press).
21. Wagner D, Young L (2003) Nontuberculous mycobacteria infections: a clinical review. Infection 31.
22. Griffith D, Aksamit T, Brown-Elliott B, Catanzaro A, Daley C, et al. (2007) An official ats/idsa statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175: 367-416.
23. Winthrop K, Chang E, Yamashita S, Iademarco M, LoBue P, (2009) Nontuberculous mycobacteria infections and anti-tumor necrosis factor-α therapy. Emerg Infect Dis 15: 1556-1561.
24. Winthrop K, Yamashita S, Beekman S, Polgreen P, (2008) Mycobacterial and other serious infections in patients receiving anti-TNF and other newly approved biological therapies; case-finding via the emerging infectious network. Clin Infect Dis 46: 1738-1740.
25. Peschon J, Torrance D, Stocking K, Glaccum M, Otten C, et al. (1998) TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 160: 943-948.
26. Marino S, Sud D, Plessner H, Lin P, Chan J, et al. (2007) Differences in reactivation of tuberculosis induced from anti-tnf treatments are based on bioavailability in granulomatous tissue. PLoS Computational Biology 3: 1909-1924.
27. Fallahi-Sichani M, Flynn J, Linderman J, Kirschner D, (2012) Differential Risk of Tuberculosis Reactivation among Anti-TNF Therapies Is Due to Drug Binding Kinetics and Permeability. The J Immun 188: 3169-78.
28. Pearson RK (1952) Exploring Data in Engineering, the Sciences, and Medicine. Oxford University Press.
29. Iseman M, Marras T, (2008) The importance of nontubercolous mycobacterial lung disease. Am J Respir Crit Care Med 178: 999-1001.
30. Bellomo N, Delitala M, (2008) From the mathematical kinetic, and stochastic game theory, to modelling mutations, onset, progression and immune competition of cancer cells. Phys Life Rev 5: 18-206.
31. Agliari E, Barra A, Gervasi Vidal K, Guerra F, (2012) Can persistent Epstein-Barr virus infection induce chronic fatigue syndrome as a Pavlov reflex of the immune response? J Biol Dyn 6: 740-762.
32. Agliari E, Barra A, Guerra F, Moauro F, (2011) A thermodynamic perspective of immune capabilities. J Theor Biol 287: 48-63.
33. Paulsson J, (2005) Models of stochastic gene expression. Phys Life Rev 2: 157-175.
34. Cooper E, (2010) Evolution of immune system from self not-self to danger to artificial immune system. Phys Life Rev 7: 55-78.
35. Falkinham JI, (2002) Nontuberculous mycobacteria in the environment. Clin Chest Med 23: 529-551.
36. Sutherland I, Bleiker M, Meijer J, Styblo K, (1983) The risk of tuberculous infection in the Netherlands from 1967 to 1979. Tubercle 64: 241-253.
37. Shanaube K, Sismanidis C, Ayles H, Beyers N, Schaap A, et al. (2009) Annual risk of tuberculous infection using different methods in communities with a high prevalence of TB and HIV in Zambia and South Africa. PLoS One 4: e7749.
38. Daniel T, Debanne S, (1997) Estimation of the annual risk of tuberculosis infection for white men in the United States. J Infect Dis 175: 1535-1537.